Trial Profile
A Randomized, Double-blind, Placebo-controlled Study Of Safety, Tolerability, And Pharmacokinetics Of Repeated Ascending Subcutaneous Doses Of SAR113244 And Pharmacodynamics Of Single Dose Of SAR113244 In Male And Female Lupus Patient
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs SAR-113244 (Primary)
- Indications Systemic lupus erythematosus
- Focus Pharmacodynamics
- Sponsors Sanofi
- 02 Jun 2016 Planned End Date changed from 1 Sep 2016 to 1 May 2017.
- 02 Jun 2016 Planned primary completion date changed from 1 Sep 2016 to 1 May 2017.
- 02 Jun 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.